Medicare Price Negotiation -- Waiting for the Other Shoe to Drop
This article was originally published in RPM Report
Executive Summary
At present, the federal government is prohibited from negotiating outpatient prescription drug prices with pharmaceutical companies on behalf of Medicare Part D. But, Senator Barack Obama (and perhaps John McCain, whose stance on this policy is unclear) favors a health system in which the government can bring its bargaining power to the table. What happens when the other shoe drops?
You may also be interested in...
Medicare Rebates: Bigger is Better, But is Big Government Best?
An inspector General report takes the first public look at rebating under Medicare Par D.For Henry Waxman the message is that private negotiation isn't working to capture deep enough discounts. But the more important message for sponsors is that the report shows CMS remains firmly committed to the private sector drug insurance model.
Health Care Reform and the Changing Dynamics Between Payers and Drug Makers
Why drug makers should pay close attention to the pressures bearing down on payers.
Greater Access - The More the Merrier
The 47 million uninsured Americans are a cause célèbre for politicians seeking to prove that the US health care system is broken. Senators Barack Obama and John McCain look upon this huge number as a national embarrassment and vow in their health care platforms to expand access aggressively.